341 related articles for article (PubMed ID: 19819536)
1. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
[TBL] [Abstract][Full Text] [Related]
2. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
[TBL] [Abstract][Full Text] [Related]
3. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
4. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
5. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
7. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
8. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
9. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
10. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
11. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
Lin DD; Schultz D; Renshaw AA; Rubin MA; Richie JP; D'Amico AV
Urology; 2005 Mar; 65(3):528-32. PubMed ID: 15780370
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
13. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
15. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
16. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
17. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
[TBL] [Abstract][Full Text] [Related]
18. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
[TBL] [Abstract][Full Text] [Related]
19. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
20. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
